GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Yu Yong reported acquisition or exercise transactions in this Form 4 filing.

GENELUX Corp Chief Scientific Officer Yu Yong received an equity award of 119,318 restricted stock units. These RSUs were granted at no cash cost under the company’s 2022 Equity Incentive Plan, increasing his directly held common stock–equivalent position to 269,024 shares, assuming full vesting.

The award vests over time: 25% will vest on the first anniversary of the grant date, with the remaining RSUs vesting in 12 equal quarterly installments thereafter. This structure is designed to tie a significant portion of the executive’s compensation to the company’s long-term share performance and ongoing service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Yu Yong

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	119,318	$0.00	--

Holdings After Transaction: Common Stock — 269,024 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSUs granted: 119,318 units Grant price: $0.00 per share Total holdings after grant: 269,024 shares +2 more

5 metrics

RSUs granted 119,318 units Restricted stock units granted to Yu Yong on 2026-06-16

Grant price $0.00 per share Stated transaction price per share for RSU grant

Total holdings after grant 269,024 shares Common stock–equivalent shares following the transaction

Initial vesting tranche 25% of RSUs Vests on first anniversary of grant date

Remaining vesting schedule 12 quarterly installments Balance of RSUs vest every 3 months after first anniversary

Key Terms

restricted stock units ("RSUs"), 2022 Equity Incentive Plan, contingent right to receive one share, vest, +1 more

5 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2022 Equity Incentive Plan financial

"RSUs granted pursuant to the Issuer's 2022 Equity Incentive Plan."

vest financial

"The RSUs will vest 25% on the first anniversary of the date of grant."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

quarterly installments financial

"The remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/18/2026 - 04:05 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Yong

(Last)

(First)

(Middle)

C/O GENELUX CORPORATION

2625 TOWNSGATE ROAD, SUITE 230

(Street)

WESTLAKE VILLAGE

CALIFORNIA

91361

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/16/2026		A⁽¹⁾		119,318	A	$0	269,024	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest 25% on the first anniversary of the date of grant, and the remaining shares shall vest in 12 equal quarterly (every 3 months) installments thereafter.

	/s/ Thomas Zindrick, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did GENELUX Corp (GNLX) disclose about Yu Yong’s recent equity award?

GENELUX disclosed that Chief Scientific Officer Yu Yong received 119,318 restricted stock units. These RSUs were granted at no cash cost and, upon vesting, will convert into an equal number of common shares, aligning his compensation more closely with shareholder value.

How many GENELUX (GNLX) shares does Yu Yong hold after this Form 4 transaction?

After the grant, Yu Yong is reported as holding 269,024 common stock–equivalent shares. This total includes the 119,318 newly granted restricted stock units, which will convert into common shares only as they vest over the defined schedule.

How do Yu Yong’s GENELUX (GNLX) RSUs vest over time?

The RSUs vest gradually. Twenty‑five percent of the 119,318 restricted stock units vest on the first anniversary of the grant date, and the remaining units vest in 12 equal quarterly installments, every three months, encouraging long-term retention and performance alignment.

What plan governs Yu Yong’s new GENELUX (GNLX) restricted stock units?

The 119,318 restricted stock units were granted under GENELUX’s 2022 Equity Incentive Plan. This plan allows the company to issue equity-based awards to executives and employees, linking a portion of their compensation directly to future company and stock performance.

Did Yu Yong buy GENELUX (GNLX) shares on the market in this Form 4?

No, the Form 4 shows an award, not an open-market purchase. Yu Yong received 119,318 restricted stock units at a stated price of $0.00 per share as part of equity compensation, rather than paying cash to buy existing GENELUX shares.